http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 16:49:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+11/26146857.html si-local-file:///var/storage/secattach/20260311/26146857.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+11/26146857.html Wed, 11 Mar 2026 16:49:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+11/26146857.html si-local-file:///var/storage/secattach/20260311/26146857.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+11/26146857.html Wed, 11 Mar 2026 16:49:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Evofem+Biosciences%2C+Inc.++For%3A+Dec+31/26146796.html si-local-file:///var/storage/secattach/20260311/26146796.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Evofem+Biosciences%2C+Inc.++For%3A+Dec+31/26146796.html Wed, 11 Mar 2026 16:44:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Evofem+Biosciences%2C+Inc.++For%3A+Dec+31/26146796.html si-local-file:///var/storage/secattach/20260311/26146796.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Evofem+Biosciences%2C+Inc.++For%3A+Dec+31/26146796.html Wed, 11 Mar 2026 16:44:00 -0400 EVFM O.07093352 http://www.streetinsider.com/Corporate+News/Evofem+Biosciences+reports+%2420.2+million+net+sales+in+2025/26146084.html <p>Evofem Biosciences Inc. (OTCID: EVFM) reported net sales of $20.2 million for the year ended December 31, 2025, marking the company's fifth consecutive year of sales growth. The San Diego-based women's health company achieved operating income of $3.4 million compared to an operating loss of $7.7 million in 2024.</p><p>The company's net sales increased 4% from $19.4 million in the prior year, driven primarily by sales of PHEXX, a hormone-free contraceptive vaginal gel, and SOLOSEC, an oral antibiotic treatment. SOLOSEC contributed to growth with a full year of sales in 2025 versus 5.5 months in 2024, after Evofem acquired the product http://www.streetinsider.com/Corporate+News/Evofem+Biosciences+reports+%2420.2+million+net+sales+in+2025/26146084.html Wed, 11 Mar 2026 16:09:45 -0400 EVFM http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Press+Releases/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html <p class="bwalignc"> — Net sales surpassed $20 million mark in FY 2025 — </p><p class="bwalignc"> — Income from operations increased to $3.4 million in FY 2025 — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evofem.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=d3321dd9a918ecac6a4c755ce81d26a9" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: </p><ul class="bwlistdisc"> <li> Achieved record net sales of $20.2 million in 2025—Evofem’s fifth consecutive year of net sales growth—mainly driven by sales of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexx.com%2F&amp;esheet=54445782&amp;newsitemid=20260311456427&amp;lan=en-US&amp;anchor=PHEXX%26%23174%3B+%28lactic+acid%2C+citric+acid%2C+and+potassium+bitartrate%29&amp;index=2&amp;md5=4cd49c7192ad90a71d826f30bcc45838" shape="rect">PHEXX® (lactic acid, citric acid, and potassium bitartrate)</a>, our hormone-free, on demand contraceptive vaginal gel. </li> <li> Reduced http://www.streetinsider.com/Business+Wire/Evofem+Reports+Fifth+Consecutive+Year+of+Net+Sales+Growth/26145946.html Wed, 11 Mar 2026 16:05:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html <p class="bwalignc"> <i>Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving </i><i>beyond legacy models</i> <i>can drive progress in women’s health</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Saundra Pelletier’s fiery keynote address at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercejpmweek.com%2F&amp;esheet=54402489&amp;newsitemid=20260123678836&amp;lan=en-US&amp;anchor=Fierce+JPM+Week+2026&amp;index=1&amp;md5=777b85eaa5ba5cdf94340963aedc410a" shape="rect">Fierce JPM Week 2026</a> is now available for on-demand viewing. </p><p> “If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.” </p><p> “Women’s health needs to be rewired and rebuilt http://www.streetinsider.com/Press+Releases/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html Fri, 23 Jan 2026 09:25:00 -0400 A.60012008 EVFM O.07093352 http://www.streetinsider.com/Press+Releases/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html <p class="bwalignc"> <i>Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving </i><i>beyond legacy models</i> <i>can drive progress in women’s health</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Saundra Pelletier’s fiery keynote address at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercejpmweek.com%2F&amp;esheet=54402489&amp;newsitemid=20260123678836&amp;lan=en-US&amp;anchor=Fierce+JPM+Week+2026&amp;index=1&amp;md5=777b85eaa5ba5cdf94340963aedc410a" shape="rect">Fierce JPM Week 2026</a> is now available for on-demand viewing. </p><p> “If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.” </p><p> “Women’s health needs to be rewired and rebuilt http://www.streetinsider.com/Press+Releases/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html Fri, 23 Jan 2026 09:25:00 -0400 A.60012008 EVFM O.07093352 http://www.streetinsider.com/Press+Releases/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html <p class="bwalignc"> <i>Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving </i><i>beyond legacy models</i> <i>can drive progress in women’s health</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Saundra Pelletier’s fiery keynote address at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercejpmweek.com%2F&amp;esheet=54402489&amp;newsitemid=20260123678836&amp;lan=en-US&amp;anchor=Fierce+JPM+Week+2026&amp;index=1&amp;md5=777b85eaa5ba5cdf94340963aedc410a" shape="rect">Fierce JPM Week 2026</a> is now available for on-demand viewing. </p><p> “If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.” </p><p> “Women’s health needs to be rewired and rebuilt http://www.streetinsider.com/Press+Releases/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html Fri, 23 Jan 2026 09:25:00 -0400 A.60012008 EVFM O.07093352 http://www.streetinsider.com/Business+Wire/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html <p class="bwalignc"> <i>Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving </i><i>beyond legacy models</i> <i>can drive progress in women’s health</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Saundra Pelletier’s fiery keynote address at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercejpmweek.com%2F&amp;esheet=54402489&amp;newsitemid=20260123678836&amp;lan=en-US&amp;anchor=Fierce+JPM+Week+2026&amp;index=1&amp;md5=777b85eaa5ba5cdf94340963aedc410a" shape="rect">Fierce JPM Week 2026</a> is now available for on-demand viewing. </p><p> “If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.” </p><p> “Women’s health needs to be rewired and rebuilt http://www.streetinsider.com/Business+Wire/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html Fri, 23 Jan 2026 09:25:00 -0400 A.60012008 EVFM O.07093352 http://www.streetinsider.com/Business+Wire/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html <p class="bwalignc"> <i>Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving </i><i>beyond legacy models</i> <i>can drive progress in women’s health</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Saundra Pelletier’s fiery keynote address at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercejpmweek.com%2F&amp;esheet=54402489&amp;newsitemid=20260123678836&amp;lan=en-US&amp;anchor=Fierce+JPM+Week+2026&amp;index=1&amp;md5=777b85eaa5ba5cdf94340963aedc410a" shape="rect">Fierce JPM Week 2026</a> is now available for on-demand viewing. </p><p> “If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.” </p><p> “Women’s health needs to be rewired and rebuilt http://www.streetinsider.com/Business+Wire/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html Fri, 23 Jan 2026 09:25:00 -0400 A.60012008 EVFM O.07093352 http://www.streetinsider.com/Business+Wire/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html <p class="bwalignc"> <i>Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving </i><i>beyond legacy models</i> <i>can drive progress in women’s health</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Saundra Pelletier’s fiery keynote address at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercejpmweek.com%2F&amp;esheet=54402489&amp;newsitemid=20260123678836&amp;lan=en-US&amp;anchor=Fierce+JPM+Week+2026&amp;index=1&amp;md5=777b85eaa5ba5cdf94340963aedc410a" shape="rect">Fierce JPM Week 2026</a> is now available for on-demand viewing. </p><p> “If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.” </p><p> “Women’s health needs to be rewired and rebuilt http://www.streetinsider.com/Business+Wire/Evofem+CEO+Saundra+Pelletier+Calls+for+a+%E2%80%9CGround-Up+Reset%E2%80%9D+of+Women%E2%80%99s+Health+at+Fierce+JPM+Week+2026/25884811.html Fri, 23 Jan 2026 09:25:00 -0400 A.60012008 EVFM O.07093352 http://www.streetinsider.com/Press+Releases/Evofem+Expands+%E2%80%9CSay+Vagina%E2%80%9D+Campaign+With+Launch+of+Say+Vagina+Store/25873125.html <p> SAN DIEGO--(BUSINESS WIRE)-- Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the <b>Say Vagina Store</b>, expanding its groundbreaking <i>Say Vagina</i> campaign aimed at normalizing accurate anatomical language and advancing education and autonomy in women’s health. </p><p> “<i>Say Vagina</i> is an ongoing initiative designed to address the widespread censorship of proper female anatomical terms in the media, where algorithms often equate educational language with explicit content and related content is secretly buried — shadow-banned,” said Saundra Pelletier, CEO of Evofem Biosciences. “We aim to replace silence with strength, transforming shame into empowerment through language http://www.streetinsider.com/Press+Releases/Evofem+Expands+%E2%80%9CSay+Vagina%E2%80%9D+Campaign+With+Launch+of+Say+Vagina+Store/25873125.html Wed, 21 Jan 2026 11:00:00 -0400 EVFM O.07093352 http://www.streetinsider.com/Press+Releases/Evofem+Expands+%E2%80%9CSay+Vagina%E2%80%9D+Campaign+With+Launch+of+Say+Vagina+Store/25873125.html <p> SAN DIEGO--(BUSINESS WIRE)-- Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the <b>Say Vagina Store</b>, expanding its groundbreaking <i>Say Vagina</i> campaign aimed at normalizing accurate anatomical language and advancing education and autonomy in women’s health. </p><p> “<i>Say Vagina</i> is an ongoing initiative designed to address the widespread censorship of proper female anatomical terms in the media, where algorithms often equate educational language with explicit content and related content is secretly buried — shadow-banned,” said Saundra Pelletier, CEO of Evofem Biosciences. “We aim to replace silence with strength, transforming shame into empowerment through language http://www.streetinsider.com/Press+Releases/Evofem+Expands+%E2%80%9CSay+Vagina%E2%80%9D+Campaign+With+Launch+of+Say+Vagina+Store/25873125.html Wed, 21 Jan 2026 11:00:00 -0400 EVFM O.07093352